易明医药: 关于子公司获得政府补助的公告

Group 1 - The company received a government subsidy of 4.853 million yuan, which accounts for 10.57% of the audited net profit attributable to shareholders for the fiscal year 2024 [1][2] - The subsidy is related to the company's daily operations and is classified as a revenue-related government subsidy [1][2] - The expected impact of the subsidy is an increase in the company's total profit for the fiscal year 2025 by 4.853 million yuan [2] Group 2 - The accounting treatment of the subsidy will be determined based on the results of the annual audit [2] - The company emphasizes that the subsidy does not have sustainability [1] - The announcement was made by the board of directors on June 5, 2025 [2]